Peptide PROTACs Emerge as Promising Approach for Cancer Treatment
Researchers demonstrate peptide-based PROTACs can selectively degrade previously undruggable cancer targets, opening new therapeutic possibilities beyond traditional small molecule approaches.
A growing body of research is demonstrating the potential of peptide-based proteolysis targeting chimeras (PROTACs) to degrade cancer-driving proteins that have resisted traditional drug development approaches. Recent publications from multiple research groups suggest this emerging technology could expand the range of treatable cancers while offering advantages over small molecule PROTACs in certain applications.
What We Know
PROTACs represent a fundamentally different approach to drug development than conventional therapies. Rather than inhibiting a target protein’s function, PROTACs recruit the cell’s own protein disposal machinery to physically eliminate the target, offering potential advantages including activity against proteins lacking traditional “druggable” binding sites [cell-chem-bio-review].
A PROTAC molecule consists of three components: a ligand that binds the target protein, a ligand that recruits an E3 ubiquitin ligase, and a linker connecting them. When the PROTAC brings the target protein and E3 ligase into proximity, the target becomes tagged with ubiquitin chains and subsequently destroyed by the proteasome.
Why Peptides?
Most PROTACs in clinical development utilize small molecule ligands for both the target and E3 ligase. While effective, small molecules face limitations in the protein surfaces they can engage. Many oncologically relevant proteins, including transcription factors and protein-protein interaction surfaces, lack the deep binding pockets that small molecules require [nature-chem-bio-2025].
Peptide-based PROTACs offer several potential advantages:
Broader target engagement: Peptides can bind to shallow surfaces and protein-protein interfaces that small molecules cannot effectively engage. This opens the possibility of degrading targets previously considered “undruggable.”
Higher selectivity potential: Peptides can be designed to recognize specific protein conformations or post-translational modifications, potentially enabling more precise target selection.
Modularity: Peptide synthesis allows rapid generation of variants for optimization, accelerating the drug discovery process.
Natural ligand derivation: Many peptide PROTAC ligands derive from natural protein-protein interactions, providing a starting point for design.
Recent Research Findings
Several recent publications have advanced the field. A study in Nature Chemical Biology demonstrated peptide PROTACs capable of degrading c-Myc, a transcription factor implicated in numerous cancers but historically considered undruggable [nature-chem-bio-2025]. The researchers designed peptides based on known c-Myc interaction partners and successfully induced degradation in cell culture models.
Another research group reported peptide PROTACs targeting mutant KRAS, specifically the G12D variant common in pancreatic and colorectal cancers [jmc-peptide-protac]. While small molecule KRAS-targeted therapies have emerged for G12C mutations, other KRAS variants remain challenging targets. The peptide approach achieved selective degradation of mutant KRAS while sparing wild-type protein in cellular assays.
Preprint data from an academic consortium described in vivo efficacy in mouse tumor models, demonstrating that appropriately formulated peptide PROTACs can achieve tumor penetration and target degradation in living organisms [oncology-preprint].
What We Don’t Know
Peptide PROTACs remain an early-stage technology with significant questions to address before clinical translation.
Pharmacokinetic challenges: Peptides typically face obstacles including poor oral bioavailability, rapid renal clearance, and proteolytic degradation. While various strategies exist to address these issues, including cyclization, non-natural amino acids, and formulation approaches, whether peptide PROTACs can achieve the pharmacokinetic profiles needed for cancer therapy remains uncertain.
Tissue penetration: Delivering peptides to solid tumors presents challenges distinct from small molecules. The molecular weight and physicochemical properties of peptide PROTACs may limit tissue penetration and intracellular access in clinically relevant settings.
Manufacturing complexity: Peptide synthesis, while well-established, differs substantially from small molecule manufacturing. Scaling production while maintaining quality and managing costs for potential therapeutic applications requires significant process development.
Comparison with Existing Approaches
How peptide PROTACs compare to other targeted protein degradation strategies remains unclear. Small molecule PROTACs have reached clinical trials and demonstrated proof-of-concept in humans, establishing a development path. Molecular glues, another degradation approach, have produced approved cancer drugs.
Whether peptide PROTACs offer sufficient advantages to justify their additional complexity for targets where small molecule approaches work adequately is debatable. Their value likely lies in expanding the target space to proteins inaccessible by other means rather than competing directly with established modalities.
How Strong Is the Evidence?
The evidence for peptide PROTACs currently qualifies as early-stage or preclinical. The published studies demonstrate proof-of-concept for the approach but do not yet establish clinical viability.
What has been shown:
- Peptide PROTACs can induce target protein degradation in cell culture
- Selectivity for targets over related proteins appears achievable
- In vivo activity in mouse models has been reported
- Multiple targets previously considered undruggable can be engaged
What remains to be demonstrated:
- Efficacy and safety in human patients
- Acceptable pharmacokinetic profiles for therapeutic use
- Manufacturing scalability and cost-effectiveness
- Advantages over alternative approaches in head-to-head comparisons
The in vivo data reported in preprints requires peer-reviewed validation [oncology-preprint]. Mouse tumor models, while valuable for early development, often fail to predict human outcomes accurately. The gap between preclinical promise and clinical success in oncology drug development is well-documented.
What’s Next
Several developments will shape the trajectory of peptide PROTACs in the coming years.
Optimization efforts: Research groups are actively working to improve peptide PROTAC drug-like properties through chemical modification strategies. Advances in cell-penetrating peptides, cyclic peptide design, and targeted delivery systems may address current pharmacokinetic limitations.
Target selection: The field will likely focus on targets where peptide PROTACs offer clear advantages over small molecules. Transcription factors, scaffolding proteins, and proteins defined by protein-protein interactions represent priority areas.
Industry investment: Pharmaceutical company interest in targeted protein degradation has increased substantially. Whether this investment extends to peptide-based approaches, or whether companies focus on small molecule PROTACs and molecular glues with clearer development paths, will influence the field’s advancement.
Clinical translation: The first peptide PROTAC clinical trials, should they occur, would provide critical data on human pharmacokinetics and tolerability. However, the timeline for such trials remains uncertain and likely extends several years into the future.
Combination with other technologies: Integration of peptide PROTACs with other advances, including antibody-drug conjugates for tumor targeting or nanoparticle formulations for improved delivery, may overcome some current limitations.
The emergence of peptide PROTACs represents an intriguing expansion of the targeted protein degradation paradigm. While considerable work remains before clinical application, the ability to potentially degrade proteins beyond the reach of conventional drug approaches addresses a fundamental limitation in current cancer therapy. Whether this promise translates to patient benefit will depend on overcoming the substantial technical challenges that remain.
This information is provided for educational purposes only and does not constitute medical advice. Cancer treatment decisions should be made in consultation with qualified oncology professionals.
Sources & Citations
- 1
- 2
- 3
- 4
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.